There are currently 632 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Saints Mary and Elizabeth Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT05249101
Recruiting
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2024
Locations: Norton Cancer Institute Audubon, Louisville, Kentucky
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
NCT05011058
Recruiting
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, Nos, EBV Associated Lymphoma, EBV Related PTCL, Nos
Register for Updates
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: aTyr Investigative Site, Louisville, Kentucky
Conditions: Pulmonary Sarcoidosis
Register for Updates
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
NCT04419779
Recruiting
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham... Read More
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
05/31/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Type 2 Diabetes
Register for Updates
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
Recruiting
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Advanced ENT and Allergy, Louisville, Kentucky
Conditions: OSA
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
Female
Ages:
Between 18 years and 60 years
Trial Updated:
05/31/2024
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Breast Cancer
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
All
Ages:
Between 29 days and 21 years
Trial Updated:
05/31/2024
Locations: Norton Children's Hospital, Louisville, Kentucky
Conditions: Acute Myeloid Leukemia
Register for Updates
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: UofL Health Care Outpatient, Louisville, Kentucky
Conditions: Heart Failure, Systemic Inflammation
Register for Updates
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
NCT04936542
Recruiting
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Upper Limb Spasticity
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: First Urology, PSC, Louisville, Kentucky
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963
Recruiting
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/29/2024
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Intracranial Aneurysm
Register for Updates
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173
Recruiting
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for the combination. The study is focused on patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs). The study is looking at several other research questions, including: What side effects may happen from taking the study... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
Register for Updates